Your browser doesn't support javascript.
loading
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud, N; Johnson, B A; Javors, M; Roache, J D; Zanca, N A.
Afiliación
  • Ait-Daoud N; Department of Psychiatry and the Southwest Texas Addiction Research and Technology (START) Center, University of Texas Health Science Center at San Antonio, San Antonio 78229-3900, Texas, USA. tiouririne@uthscsa.edu
Alcohol Clin Exp Res ; 25(6): 847-9, 2001 Jun.
Article en En | MEDLINE | ID: mdl-11410720
BACKGROUND: Recently, we showed by using self-report that combining ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day) was effective at reducing drinking and increasing abstinence among early-onset alcoholics (EOAs), who are characterized by a range of antisocial behaviors and high biological and familial disease predisposition. Here, we investigated whether the self-reported differences in drinking would be corroborated by measurements of serum carbohydrate-deficient transferrin (CDT) level, a sensitive, reliable, and well-validated marker of transient alcohol consumption. METHOD: An 8-week double-blind clinical trial was performed in which 20 EOAs were randomized to receive ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day) or placebo as an adjunct to weekly standardized cognitive behavioral therapy. Serum CDT was assessed at weeks 0 (baseline), 4, and 8. RESULTS: Log serum CDT was significantly lower in the ondansetron and naltrexone group (group mean, 1.44 +/- 0.076) compared with the placebo group (group mean, 1.82 +/- 0.113), as evidenced by a main effect of group [F(1,15) = 7.2, p = 0.017; effect size = 0.32], visit [F(1,16) = 11.2, p = 0.004; effect size = 0.41], and an interaction between group and visit [F(1,16) = 27.54, p < 0.001; effect size = 0.63]. CONCLUSIONS: The combination of ondansetron plus naltrexone was superior to placebo at reducing serum CDT. This corroborated our self-reported drinking data and demonstrated that the medication combination is an effective treatment for EOAs.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Consumo de Bebidas Alcohólicas / Transferrina / Biomarcadores / Ondansetrón / Alcoholismo / Naltrexona Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: Alcohol Clin Exp Res Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Consumo de Bebidas Alcohólicas / Transferrina / Biomarcadores / Ondansetrón / Alcoholismo / Naltrexona Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Revista: Alcohol Clin Exp Res Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido